肺癌的免疫治疗

doi:10.3760/cma.j.issn.1673-422X.2015.10.016

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (10): 776-779.doi: 10.3760/cma.j.issn.1673-422X.2015.10.016

肺癌的免疫治疗

张淑娟,常建华

200032 上海，复旦大学附属肿瘤医院肿瘤内科（张淑娟、常建华）;复旦大学上海医学院肿瘤学系;新疆维吾尔自治区喀什地区第二人民医院肿瘤科（张淑娟）

出版日期:2015-10-08 发布日期:2015-09-08
通讯作者: 常建华 E-mail:changjianhua@163.com
基金资助:
上海市科学技术委员会科研计划（124119a6200）

The immunotherapy of lung cancer

Zhang Shujuan, Chang Jianhua

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University， Shanghai 200032, China； Department of Medical Oncology, Kashi No.2 Peoples′ Hospital of the Xinjiang Uygur Autonomous Region, Kashi 844000, China

Online:2015-10-08 Published:2015-09-08
Contact: Chang Jianhua E-mail:changjianhua@163.com

摘要/Abstract

摘要： 肺癌的常规治疗疗效有限，目前免疫治疗已成为肺癌治疗新选择。多个临床研究初步证实了伊匹木单抗、程序性死亡受体1抗体、免疫细胞、细胞因子、黑色素瘤相关抗原A3蛋白疫苗、BLP25脂质体疫苗、BelagenpumatucelL和多肽疫苗等对肺癌的治疗效果，且多数已进入Ⅲ期临床研究阶段，有望成为肺癌综合治疗的重要组成部分。

关键词: 肺肿瘤, 免疫法, 被动, 抗体, 单克隆

Abstract: Lung cancer is characterized by high malignancy and the majority of patients are diagnosed at the advanced or late stage. Chemoradiotherapy has insufficient effect on this malignant tumor. At present the immune therapy has become a new choice for lung cancer treatment. Ipilimumab, antibody to programmed death1, immune cells, cytokines, melanomaassociated antigen A3 vaccine, liposomal BLP25, belagenpumatucelL and polypeptide vaccine have been proved effective for lung cancer through various clinical trials. Futhermore, most of them have been moved forward to phase Ⅲ clinical trials in order to get more strong evidence to support the immunotherapy incorporated into the multidisciplinary treatment of lung cancer.

Key words: Lung neoplasms, Immunity, passive, Antibody, monoclonal

张淑娟,常建华. 肺癌的免疫治疗[J]. 国际肿瘤学杂志, 2015, 42(10): 776-779.

Zhang Shujuan, Chang Jianhua. The immunotherapy of lung cancer[J]. Journal of International Oncology, 2015, 42(10): 776-779.

参考文献

［1］ Jemal A, Siegel R, Xu J , et al. Cancer statistics, 2010［J］. CA Cancer J Clin, 2010, 60(5): 277-300. ［2］ Crinò L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (nonmetastatic) nonsmallcell lung cancer: ESMO clinical practice guidelines for diagnosis， treatment and followup［J］. Ann Oncol, 2010, 21 Suppl 5: v103-v115. ［3］ Tucker ZC, Laguna BA, Moon E, et al. Adjuvant immunotherapy for non-small cell lung cancer［J］. Cancer Treat Rev, 2012, 38 (6): 650-661. ［4］ Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age［J］. Nature, 2011, 480(7378): 480-489. ［5］ Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as firstline treatment in stage ⅢB/Ⅳ nonsmall cell lung cancer: results from a randomized, doubleblind, multicenter phase Ⅱ study ［J］. J Clin Oncol, 2012, 30(17): 2046-2054. ［6］ Garon EB, Balmanoukian A, Hamid O, et al. MK3475 monotherapy for previously treated nonsmall cell lung cancer (NSCLC): preliminary safety and clinical activity［J］. Clin Cancer Res, 2014, 20(Suppl 2): A20. ［7］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. ［8］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in advanced squamouscell nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(2): 123-135. ［9］ Li R, Wang C, Liu L, et al. Autologous cytokineinduced killer cell immunotherapy in lung cancer: a phase Ⅱ clinical study［J］. Cancer Immunol Immunother, 2012, 61(11): 2125-2133. ［10］ Kilic A, Landreneau RJ, Luketich JD, et al. Density of tumorinfiltrating lymphocytes correlates with disease recurrence and survival in patients with large nonsmallcell lung cancer tumors［J］. J Surg Res, 2011, 167(2): 207-210. ［11］ Liu H, Zhang T, Ye J, et al. Tumorinfiltrating lymphocytes predict response to chemotherapy in patients with advance nonsmall cell lung cancer［J］. Cancer Immunol Immunother, 2012, 61(10): 1849-1856. ［12］ Iwai K, Soejima K, Kudoh S, et al. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study［J］. Cancer Immunol Immunother, 2012, 61(10): 1781-1790. ［13］ Liu JF, Liu F, Qi YC, et al. Studies on IFNgamma mediated reversion of CIK killing sensitivity to edited human lung cancer A549 cells［J］. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2010, 26(4): 354-355, 358. ［14］ Ridolfi L, Bertetto O, Santo A, et al. Chemotherapy with or without lowdose interleukin2 in advanced nonsmall cell lung cancer: results from a phase Ⅲ randomized multicentric trial［J］. Int J Oncol, 2011, 39(4): 1011-1017. ［15］ Ratto GB, Costa R, Maineri P, et al. Neoadjuvant chemo/immunotherapy in the treatment of stage Ⅲ (N2) nonsmall cell lung cancer: a phase Ⅰ/Ⅱ pilot study［J］. Int J Immunopathol Pharmacol, 2011, 24(4): 1005-1016. ［16］ Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage ⅢB or Ⅳ non-small-cell lung cancer receiving BLP25 liposome vaccine (LBLP25): phase ⅡB randomized, multicenter, openlabel trial ［J］. J Cancer Res Clin Oncol, 2011, 137(9): 1337-1342. ［17］ Thomas A, Hassan R. Immunotherapies for nonsmallcell lung cancer and mesothelioma［J］. Lancet Oncol, 2012, 13(7): e301-e310. ［18］ Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase Ⅱ trial of belagenpumatucelL, a TGFbeta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther, 2009, 16(8): 620-624.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[6]	秦雪倩, 杨宏宇, 王真, 王孟超, 张欣. 双特异性抗体在非小细胞肺癌治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(9): 558-563.
[7]	岳红云, 张百红. 免疫检查点激动剂治疗实体瘤的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 290-293.
[8]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[9]	左小平, 刘晓川, 吴西强, 李周, 夏天, 刘国凤. 老年早期肺癌患者经胸腔镜肺切除术后心律失常发生的危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(12): 711-716.
[10]	陈郁, 许华, 刘海, 陈士新. 基于CT影像学特征的恶性肺纯磨玻璃结节患者病理分型预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(11): 655-660.
[11]	许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(1): 1-11.
[12]	张万芳, 王尤, 苏晶, 陈刚, 周福祥. 肺原发尤文肉瘤/原始神经外胚层瘤1例[J]. 国际肿瘤学杂志, 2023, 50(1): 62-64.
[13]	杨莎, 杨晓华, 王苏华, 薛晓燕, 徐俊. 老年肺癌胸腔镜手术后下肢深静脉血栓的危险因素分析及预测模型的建立和验证[J]. 国际肿瘤学杂志, 2022, 49(9): 532-536.
[14]	王津, 张耀圣, 孙婷婷, 王丹, 胡乃东. 以前胸壁聚集性多发蕈状肿物为表现的肺腺鳞状细胞癌皮肤转移1例[J]. 国际肿瘤学杂志, 2022, 49(9): 575-576.
[15]	陈煌婧, 朱鹏飞, 张晴, 陈桂芳, 杨春林, 何英. 超声造影和CT引导下经皮穿刺活检在周围型肺肿块诊断中临床价值的比较[J]. 国际肿瘤学杂志, 2022, 49(8): 459-463.

肺癌的免疫治疗

The immunotherapy of lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价